Ora Banda Mining Ltd (ASX:OBM) is reviewing its Davyhurst gold operations due to production and cost performance issues.
The company recently completed stage one of the review, resulting in a 24-month plan to improve productivity, lower costs and build cash to invest back into exploration and next mine resource development.
Open Orphan PLC (AIM:ORPH, OTC:OPORF)'s executive chairman expects to attract more high-quality long-term investors following the end of the lock-up arrangement with Poolbeg Pharma over legacy in specie shares.
Cathal Frie said: "Due to the nature of the lock-up period, which was designed to allow for an orderly market following Poolbeg's admission to AIM, prospective investors looking to build more substantial stakes were unable to do so.
Cellular Goods PLC (LSE:CBX) said it is seeking further clarification from the UK Food Standards Authority (FSA) on the status of its range of ingestible cannabinoid (CBD) products.
The FSA's current position is that any new products not on sale before February 2020 will not be eligible for the public list and therefore should not be available for sale.
Diversified Energy Company PLC (LSE:DEC, OTCQX:DECPF) told investors that it is now positioned as the first company in the US to deploy certain state-of-the art emissions measurement devices in natural gas upstream operations.
It notes that earlier equipment was capable only of visually detecting fugitive methane emissions, while newer technology being used by the company (the Opgal EyeCGas 2.0, EyeCSite software, and the Semtech Hi-Flow 2 sampler) take the next logical step and estimate the amount of emissions.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive, Tim McCarthy, described as a ‘significant milestone’ the successful completion of a pharmacokinetic (PK) study of its lead asset Lupuzor, also known as P140.
PK studies are there to assess how the body absorbs, distributes, metabolises, and excretes a compound.
Bradda Head Lithium Ltd said it successfully completed and closed its UK placing, raising gross proceeds of about £1.96mln.
The North America-focused lithium development group placed 14.5mln shares at 13.5 pence each having received orders in excess of £6.6mln.
Imugene Ltd (ASX:IMU, OTC:IUGNF) and collaborator City of Hope®, one of the largest cancer research and treatment organisations in the United States, has dosed the first cohort two patient in the phase one clinical trial of its oncolytic virotherapy candidate, CHECKvacc.
Imugene is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Jo Battershill, Anglesey Mining PLC (LSE:AYM)’s chief executive, has bought a further 300,000 shares at 4.1p each. It takes his total holding to 2.09mln shares approximately.
Vast Resources PLC (AIM:VAST) said Atlas Special Opportunities has converted US$300,000 of bonds into 48.4mln shares at a price of 0.48p per share.